Since it was founded in 2000 in Grenoble, France, PX'Therapeutics (formerly known as Protein'eXpert) has been offering contract-research, development and manufacturing services for recombinant proteins and monoclonal antibodies. 

Our services range from protein engineering, optimisation of drug candidates, humanisation of antibodies, to the production and release of GMP batches for clinical studies. 

Our company is organised around technological platforms that ensure the use and improvement of state-of-the-art technologies to address specific requests from our customers. We elaborate relevant scientific programmes and work closely with our customers to fully meet their expectations and bring value to their projects.

With a portfolio of more than 240 customers, and 60% of our turnover being generated out of France, we aim to become one of the leading European Contract Development and Manufacturing Organisations.

2000 Creation of Protein’eXpert, CRO devoted to the engineering, development and production of valuable recombinant proteins

• 2004 Set up of the subsidiary PX’Pharma offering GMP clinical manufacturing services using microbial expression systems

• 2007 Set up of the subsidiary PX’Monoclonals in Lyon dedicated to the development of murine and humanized monoclonal antibodies for research and therapeutic purposes

• 2008 Protein’eXpert changes name to PX’Therapeutics in order to highlight its focus on integrated biotherapeutics development

• 2010 (Q3) Creation of a new subsidiary PROMISE Advanced Proteomics offering unique protein Absolute Quantification services

• 2010 (Q4) Opening of new GMP mammalian cell culture manufacturing facility

• 2012 Acquisition of PX'Therapeutics by Aguettant, pharmaceutical company based in France